A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with poor prognosis and a significant unmet medical need. This study evaluated the safety, pharmacokinetics (PK) and target engagement in the lungs, of GSK3008348, a novel inhaled alpha-v beta-6 (αvβ6) integrin in...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M., Simpson, Juliet K., Porter, Joanna C., Wilson, Frederick J., Chan, Robert, Eames, Rhena, Cui, Yi, Siederer, Sarah, Parry, Simon, Kenny, Julia, Slack, Robert J., Sahota, Jagdeep, Paul, Lyn, Saunders, Peter, Molyneaux, Philip L., Lukey, Pauline T., Rizzo, Gaia, Searle, Graham E., Marshall, Richard P., Saleem, Azeem, Kang’ombe, Arthur R., Fairman, David, Fahy, William A., Vahdati-Bolouri, Mitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099768/
https://www.ncbi.nlm.nih.gov/pubmed/32216814
http://dx.doi.org/10.1186/s12931-020-01339-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099768/
https://www.ncbi.nlm.nih.gov/pubmed/32216814
http://dx.doi.org/10.1186/s12931-020-01339-7

Ejemplares similares